Martin Shkreli has no regrets.

The Taste of Future Sister-in-lawposter boy for greedy drug companies who became a public figure in 2015 when he raised the price of an HIV medication by 4,000 percent overnight, would do it all again.

Shkreli said in an interview with Bloomberg on Friday that he would "of course" make the same decision today.

“In terms of regret, maybe not seeing that as acutely would’ve been a minor regret,” Shkreli said, referring to public outrage at his actions. “But because the price increase has stuck, so to speak, I don’t really, that’s the main mission, which was to raise the price and have it generate increased revenue ,that’s happened, so I’m happy with respect to that.”

Shkreli is part of a cadre of pharmaceutical executives who have come under public scrutiny for price hikes. Almost a year after Shkreli's price increase, the pharmaceutical company Mylan became the focus of public outrage when consumers started noticing that the company had systematically raised the price of the EpiPen over nearly a decade.

Mylan has tried to recover from the public relations blow by introducing a generic version of the life-saving allergy tool. Shkreli hasn't done much at all to rehabilitate his own image. He told Bloomberg that the reaction to his price hike was "blown out of proportion."

Shkreli will go on trial this summer for illegal financial maneuvers at his former company.